Core Insights - Voyager Therapeutics is focusing on 2025 as the "year of tau," with two key assets targeting tau-related conditions [2] - The company anticipates tau PET imaging data from a multiple ascending dose study by the end of the year [2] - A gene therapy asset aimed at tau knockdown, similar to BIIB080, is expected to have significant readouts in the mid-year timeframe [2] Group 1 - The first asset is a C-terminal antibody targeting tau, with imaging data expected soon [2] - The second asset is a gene therapy for tau knockdown, which is part of the company's broader strategy [2] - Voyager is introducing newly discovered blood-brain barrier (BBB) penetrant capsids into clinical trials for the first time this year [3] Group 2 - The company has two assets utilizing these capsids: the tau knockdown gene therapy and a partnered program for Friedreich's ataxia [3] - Voyager aims to establish proof of concept for the efficacy of its capsids in producing gene expression [3]

Voyager Therapeutics Conference Call Summary Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Focus**: Development of gene therapies targeting neurodegenerative diseases, particularly Alzheimer's disease Key Industry Insights - **Year of Tau**: 2026 is referred to as the "year of tau" for Voyager, emphasizing the company's focus on tau-related therapies [2] - **Tau vs. A-beta**: The discussion highlights the ongoing debate regarding the role of tau and amyloid-beta (A-beta) in Alzheimer's disease, with evidence suggesting tau may be a more significant driver of cognitive decline [4][5][6] Core Developments 1. **Tau-targeted Assets**: - Two main assets targeting tau: an antibody and a gene therapy for tau knockdown [2] - Anticipated tau PET imaging data by the end of 2026 [2] - Gene therapy aims for a robust knockdown of tau in the brain, with expected reductions in the 50%-75% range across various cortical regions [12] 2. **Capsid Technology**: - Introduction of newly discovered blood-brain barrier (BBB)-penetrant capsids into clinical trials [2] - Two programs utilizing these capsids: one for tau knockdown and another partnered with Neurocrine for Friedreich's ataxia [3] - The goal is to demonstrate proof of concept for gene expression in the brain [3] 3. **Regulatory Engagement**: - Positive interactions with the FDA regarding the development of the tau knockdown gene therapy program [15][17] - Plans to use tau PET imaging to assess the reduction of pathological tau as a primary endpoint [17] Clinical Development and Strategy - **BIIB080 Data**: The upcoming data from BIIB080 is expected to be a significant catalyst for the gene therapy program, providing insights into the necessary tau reduction for clinical benefits [8][10] - **Antibody Development**: Voyager's antibody approach focuses on specific pathological forms of tau, with hopes of demonstrating efficacy in tau PET imaging and clinical outcomes [20][22][29] Market Considerations - **Timing of Intervention**: The company believes that interventions targeting tau may not need to occur as early as those targeting amyloid, suggesting a potential window for treatment even in mild to moderate dementia stages [30][34] - **Partnership Strategy**: Voyager is actively seeking partnerships to expand its reach and capabilities, leveraging collaborations with companies like Neurocrine, Novartis, and AstraZeneca [44][46] Additional Insights - **Novel Shuttle Technology**: Voyager is exploring the use of ALPL as a receptor for BBB penetration, which may offer advantages over traditional methods [37][39] - **Safety Considerations**: The potential safety risks associated with ALPL are acknowledged, particularly concerning severe loss of function leading to hypophosphatasia [43] Conclusion Voyager Therapeutics is positioned to make significant advancements in the treatment of neurodegenerative diseases, particularly through its focus on tau-targeted therapies and innovative delivery mechanisms. The upcoming data releases and regulatory interactions will be critical in shaping the company's future trajectory in the biotech landscape.

Core Viewpoint - Voyager Therapeutics, Inc. is a biotechnology company focused on developing genetic treatments for neurological diseases, with a strong emphasis on innovative therapies and a promising financial outlook despite a negative EPS [1][6] Financial Performance - For the quarter ending March 9, 2026, Voyager reported an EPS of -$0.46, which was below the estimated -$0.40, but the revenue of $15.34 million exceeded the estimated $10 million by 57.97% and showed significant growth from $6.28 million in the same quarter last year [2][6] - The quarterly loss of $0.46 per share was better than the Zacks Consensus Estimate of a $0.54 loss, resulting in a positive surprise of 15.08% [3][6] Financial Health - Voyager has a strong cash position of $202 million, which is expected to sustain operations until 2028, and a low debt-to-equity ratio of 0.19, indicating a relatively low level of debt compared to equity [4][6] - The company has a robust current ratio of 7.64, suggesting a strong ability to cover short-term liabilities with short-term assets [4] Valuation Metrics - Voyager's price-to-earnings (P/E) ratio is approximately -2.01, reflecting negative earnings, while the price-to-sales ratio is about 5.66 and the enterprise value to sales ratio is approximately 4.95 [5]

分组1 - Voyager Therapeutics reported a quarterly loss of $0.46 per share, better than the Zacks Consensus Estimate of a loss of $0.54, and improved from a loss of $0.59 per share a year ago, resulting in an earnings surprise of +15.08% [1] - The company posted revenues of $15.34 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 57.97%, compared to revenues of $6.28 million in the same quarter last year [2] - Voyager Therapeutics has surpassed consensus EPS estimates two times over the last four quarters and has also topped consensus revenue estimates twice during the same period [2] 分组2 - The stock has lost about 0.8% since the beginning of the year, while the S&P 500 has declined by 1.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $9.65 million, and for the current fiscal year, it is -$1.39 on revenues of $84.73 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Position - Voyager ended 2025 with a cash position of $202 million, expected to maintain runway into 2028[1] - Cash, cash equivalents, and marketable securities decreased to $201,691,000 in 2025 from $332,388,000 in 2024[19] - Total assets decreased to $252,281,000 in 2025 from $393,050,000 in 2024[19] - Total stockholders' equity decreased to $196,081,000 in 2025 from $299,760,000 in 2024[19] - Deferred revenue significantly decreased to $1,590,000 in 2025 from $30,397,000 in 2024[19] Revenue and Collaboration - Collaboration revenue for Q4 2025 was $15.3 million, up from $6.3 million in Q4 2024, while total collaboration revenue for 2025 was $40.4 million, down from $80.0 million in 2024[7] - Collaboration revenue for Q4 2025 was $15,336,000, a 144.5% increase from $6,278,000 in Q4 2024[19] - Net collaboration revenue for the year ended December 31, 2025, was $32,268,000, down from $71,538,000 in 2024[23] Expenses - R&D expenses for Q4 2025 were $36.0 million, slightly up from $35.6 million in Q4 2024, and total R&D expenses for 2025 were $134.7 million, compared to $127.4 million in 2024[7] - General and administrative expenses for Q4 2025 were $9.3 million, compared to $9.0 million in Q4 2024, with total G&A expenses for 2025 at $37.5 million, up from $35.9 million in 2024[7] - Total operating expenses for Q4 2025 were $45,268,000, slightly up from $44,577,000 in Q4 2024[19] - Net research and development expenses for the year ended December 31, 2025, were $126,568,000, compared to $118,905,000 in 2024[23] Net Loss - Net loss for Q4 2025 was $27.4 million, an improvement from a net loss of $34.5 million in Q4 2024, while total net loss for 2025 was $119.7 million, compared to $65.0 million in 2024[7] - Net loss for Q4 2025 was $27,426,000, compared to a net loss of $34,487,000 in Q4 2024, representing a 20.5% improvement[19] - Net loss per share, basic, for Q4 2025 was $0.47, an improvement from $0.59 in Q4 2024[19] Development and Clinical Trials - VY1706 (tau-silencing gene therapy) is expected to achieve first-in-human dosing in H2 2026, with IND application submission anticipated in Q2 2026[3] - VY7523 (anti-tau antibody) completed enrollment in a clinical trial in Q4 2025, with tau PET imaging data expected in H2 2026[3] - Voyager paused development of its APOE gene therapy program to prioritize more advanced programs, unrelated to prior data[7] - Neurocrine intends to initiate a clinical trial with NBIB-'223 for Friedreich's ataxia in H2 2026, pending successful FDA IND clearance[3] Future Financial Expectations - Voyager anticipates potential non-dilutive capital of up to $2.4 billion in development milestone payments[9]

Financial Performance - The company reported a net income of $132.3 million for the year ended December 31, 2023, but has a history of significant losses, with net losses of $119.7 million and $65.0 million for the years ended December 31, 2025 and 2024, respectively [687]. - The company has an accumulated deficit of $445.9 million as of December 31, 2025, and expects to continue incurring significant expenses and operating losses in the foreseeable future [687]. - The net loss for 2025 was $119.7 million, compared to a net loss of $65.0 million in 2024, representing an increase in loss of 84.3% [708]. - The company reported a loss before income taxes of $119.6 million in 2025, compared to a loss of $64.3 million in 2024, an increase of 85.9% [708]. Revenue and Collaboration - The company recognized $30.5 million in collaboration revenue from the 2023 Neurocrine Collaboration Agreement for the year ended December 31, 2025, along with additional revenues from other collaboration agreements totaling $40.4 million [690]. - Collaboration revenue decreased to $40.4 million in 2025 from $80.0 million in 2024, a decline of 50% [709]. - Collaboration revenue for 2024 was $80.0 million, down from $250.0 million in 2023, a decrease of 68% [715]. - The company has potential to earn up to $6.8 billion in milestone payments across its partnered portfolio, including $2.4 billion in potential development milestone payments [683]. - The company has entered into multiple collaboration and licensing agreements, delivering over $500 million in non-dilutive funding to date [683]. Research and Development - Research and development expenses are expected to decrease in the near term due to portfolio prioritization and alignment of operating expenditures with current capital resources [693]. - Research and development expenses rose to $134.7 million in 2025, up from $127.4 million in 2024, an increase of 5.7% [710]. - Research and development expenses increased significantly by $35.2 million from $92.2 million in 2023 to $127.4 million in 2024, an increase of 38.2% [716]. - Total research and development expenses increased to $127.4 million in 2024 from $92.2 million in 2023, representing a change of $35.2 million or 38.2% [717]. - Internal research and development expenses rose to $38.4 million in 2024 from $27.9 million in 2023, an increase of $10.6 million or 38.1% [717]. - The company expects to continue incurring research and development expenses as clinical trials progress and marketing approvals are sought [734]. - The company has paused investment in its apolipoprotein E gene therapy program to prioritize other programs, despite demonstrating dose-dependent APOE4 protein reduction in murine studies [678]. - The company is advancing its proprietary pipeline, including VY1706, which showed a 50% to 73% reduction in tau mRNA levels in a non-human primate study, and VY7523, which reduced tau spread by approximately 70% in preclinical studies [677]. - The company initiated a Phase 1 multiple ascending dose clinical trial of VY7523 in early AD patients in February 2025, with initial tau PET imaging data expected in the second half of 2026 [677]. - The company expects to submit an investigational new drug application for VY1706 in the second quarter of 2026 and initiate a clinical trial in the second half of 2026 [677]. Operating Expenses - Total operating expenses increased to $172.2 million in 2025 from $163.3 million in 2024, an increase of 5.5% [708]. - General and administrative expenses increased to $37.5 million in 2025 from $35.9 million in 2024, a rise of 4.5% [711]. - Other income, net decreased to $12.3 million in 2025 from $19.0 million in 2024, a decline of 35.4% [712]. - Net cash used in operating activities was $15.3 million in 2024, driven by a net loss of $65.0 million and a decrease in deferred revenue of $44.8 million [724]. - Net cash used in investing activities was $94.9 million in 2024, primarily due to $465.7 million for purchases of marketable securities [727]. Cash and Financing - Cash, cash equivalents, and marketable securities totaled $201.7 million as of December 31, 2025, expected to meet operating expenses into 2028 [735]. - Net cash provided by financing activities was $114.0 million in 2024, mainly from $93.5 million in net proceeds from a public offering of common stock and warrants [732]. Market Risks - The company is primarily exposed to market risk related to interest rate sensitivity, particularly due to investments in money market funds and marketable securities [746]. - An immediate 100 basis point change in interest rates is not expected to have a material effect on the fair market value of the company's investment portfolio [746]. - The company is not currently exposed to market risk from foreign currency exchange rates but may face such risks in future contracts with vendors in Asia and Europe [747]. - Inflation has not had a material effect on the company's business, financial condition, or results of operations for the year ended December 31, 2025 [747].

Core Insights - Voyager Therapeutics anticipates 2026 to be a transformative year, focusing on tau-targeting assets for Alzheimer's disease, novel I.V.-delivered neuro gene therapies, and the advancement of its nonviral delivery platform, Voyager NeuroShuttle [2][4] Financial Position - As of December 31, 2025, Voyager reported a cash position of $201.7 million, which is expected to sustain operations into 2028 [7][8] - Collaboration revenue for Q4 2025 was $15.3 million, up from $6.3 million in Q4 2024, while total collaboration revenue for the year was $40.4 million, down from $80.0 million in 2024 [12][20] Research and Development Highlights - The company expects to complete a GLP toxicology study for VY1706 in Q1 2026, with an IND application submission planned for Q2 2026 and first-in-human dosing anticipated in H2 2026 [5][6] - VY7523's clinical trial for Alzheimer's disease completed enrollment in Q4 2025, with tau PET imaging data expected in H2 2026 [6][12] Partnerships and Collaborations - Neurocrine plans to initiate a clinical trial with NBIB-'223 for Friedreich's ataxia in H2 2026, pending FDA IND clearance [6] - Voyager's partnership with Novartis for Huntington's disease and spinal muscular atrophy continues to advance [6] Pipeline Updates - Voyager has paused development of its apolipoprotein E gene therapy program to prioritize more advanced programs, despite demonstrating promising results in murine studies [5][6] - The Voyager NeuroShuttle platform has shown sustained brain exposure in a proof-of-concept study, indicating potential for high brain penetration with genetic medicines [5][6]

Core Insights - Voyager Therapeutics is focusing on three key pillars of value for the upcoming year, with a significant emphasis on the tau target and gene therapy initiatives [2]. Group 1: Company Overview - Voyager Therapeutics has outlined an important year ahead, highlighting its strategic focus on the tau target with two specific therapeutic approaches [2]. - The company plans to advance two different gene therapy assets into clinical trials, leveraging its innovative blood-brain barrier penetrant capsids [3].

Summary of Voyager Therapeutics FY Conference Call Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Industry**: Biotechnology, specifically focusing on gene therapy and treatments for neurodegenerative diseases, particularly Alzheimer's disease Key Points 1. Strategic Focus Areas - **Three Pillars of Value**: - **Tau Target**: Focus on tau as a target for Alzheimer's with two programs: VY7523 (anti-tau antibody) and VY-1706 (gene therapy) [2][3] - **Gene Therapy**: Plans to advance two gene therapy assets into clinical trials, one in partnership with Neurocrine and one wholly owned by Voyager [2] - **NeuroShuttle Platform**: Development of a platform to deliver various drugs across the blood-brain barrier [3] 2. Tau as a Target for Alzheimer's - **Importance of Tau**: The spread of tau in the brain correlates more closely with clinical decline in Alzheimer's than amyloid accumulation [6] - **Recent Developments**: Upcoming data from J&J and Biogen on tau-targeting therapies will provide further validation for tau as a target [5][6] - **Mixed Results from Competitors**: UCB's bepranemab showed some effect on tau spread but failed to meet primary clinical endpoints, indicating the complexity of targeting tau [8][9] 3. Clinical Development Insights - **VY7523**: Preliminary safety data shows a favorable profile, with a brain-to-plasma ratio of 0.3% and a half-life supporting monthly dosing [20] - **MAD Study Design**: The multiple ascending dose (MAD) study is designed to assess the effect on tau PET imaging, which is the key biomarker for evaluating the spread of pathological tau [21] - **Future Studies**: Plans to include tau PET imaging data in future studies and emphasize its importance over fluid-based biomarkers [24][25] 4. Gene Therapy Developments - **VY-1706**: Aiming for a 50%-70% reduction in tau mRNA/protein, with a focus on lower doses to enhance safety and reduce costs [31] - **FDA Interactions**: Productive discussions with the FDA regarding trial designs and plans to file an IND in Q2 2026 [33] 5. NeuroShuttle Platform - **Differentiation**: The ALPL shuttle shows longer half-life and no adverse effects on reticulocyte counts compared to transferrin receptor shuttles, making it a promising delivery method for various therapies [46] - **Therapeutic Modalities**: Exploring antibodies, peptides, and oligonucleotides for use with the NeuroShuttle platform [47] 6. Partnerships and Collaborations - **Neurocrine Partnership**: Progress on gene therapy programs, including FA and GBA1, with plans to enter the clinic this year [48] 7. Market Opportunities - **Alzheimer's Disease**: The potential for anti-tau therapies to be used in combination with anti-amyloid treatments, especially for patients who do not respond to the latter [41] - **Broader Applications**: Potential to address other tauopathies beyond Alzheimer's, expanding the market opportunities for Voyager's therapies [42] Additional Insights - **Clinical Predictions**: Anticipation that BIIB080 will show significant effects in clinical measures, which could influence Voyager's approach to VY-1706 [36] - **Patient Population**: Targeting early Alzheimer's patients for clinical trials, aligning with trends in the amyloid treatment landscape [26][27] This summary encapsulates the key discussions and insights from the Voyager Therapeutics FY Conference, highlighting the company's strategic focus, clinical developments, and market opportunities in the biotechnology sector.

Core Viewpoint - Voyager Therapeutics, Inc. (NASDAQ:VYGR) is recognized as a promising micro-cap stock by analysts, particularly following its strong Q3 performance and significant cash reserves [1][2]. Financial Performance - Voyager reported a loss per share of $0.47 for Q3 2025, which was $0.05 better than analyst expectations [3]. - The company's revenue for the quarter exceeded $13 million, representing a nearly 45% decline compared to the same period last year, but it surpassed market estimates by $5.5 million [3]. - Voyager ended the quarter with $229 million in cash, providing operational runway into 2028, and remains eligible for up to $2.4 billion in partner milestones [2]. Analyst Coverage - HC Wainwright has lowered the price target for Voyager from $30 to $25 while maintaining a Buy rating on the shares, reflecting confidence in the company's future despite the price adjustment [2]. Company Focus - Voyager Therapeutics is a biotechnology company that specializes in human genetics aimed at curing neurological diseases [4].